Joseph R. Carver, MD

Transcription

1 Holly Auer Holly Auer is Penn Medicine s Corporate Director of Communications. She leads the daily operations and long-term planning initiatives for Penn Medicine's Communications department, managing a staff of 12 communications professionals focusing on media relations, internal publications, and social media. She came to Penn in 2007 after spending the early part of her career as a newspaper health care reporter, during which time she specialized in coverage of underpublicized issues relating to vulnerable populations including women, children, minorities and low-income families. She previously worked for The Buffalo News, The Post & Courier in Charleston, S.C. and the Scripps Howard News Service in Washington, D.C., and freelanced for magazines including Glamour, Self and Prevention. She is the recipient of numerous national and statewide awards for her writing and editing as both a journalist and a public relations professional, and twice was awarded the Association of American Medical Colleges top prizes for excellence in communications and public relations, including for her leadership of the book project To Spread the Light of Knowledge: 250 Years of the Nation s First Medical School, and a yearlong slate of other communications activities to mark this historic milestone at Penn Medicine. She is a graduate of Syracuse University, where she majored in magazine journalism, and she earned a master s degree in bioethics at Penn.

2 Joseph R. Carver, MD Joseph R. Carver, MD is the Bernard Fishman Clinical Professor of Medicine, Director of the Penn Cardiology Fellow's Practice, Senior Administrative Officer of the Abramson Family Cancer Research Institute, and Chief of Staff of the Abramson Cancer Center. A graduate of Temple University, Dr. Carver completed his medical training at Hahnemann University School of Medicine. In the past he has served on the staffs of Hahnemann, Jeanes and the American Oncologic Hospital. For the 10 years prior to joining Penn, Dr. Carver served as a Corporate Medical Director for Aetna U.S. Healthcare. Dr. Carver brings extensive administrative experience to the Abramson Cancer Center having served on the Board of Directors of numerous for-profit and non-profit organizations. He has served on the Board of Overseers of Penn s Nursing School and recently helped lead efforts to have insurance companies support cancer clinical trials. Dr. Carver has authored over 100 medical papers and monographs and was honored as the IS Ravdin Master Clinician in 20l2 and is currently a member of Penn s Academy of Master Clinicians. He has been consistently named as one of Philadelphia Magazine s Top Doctors. His expertise in the treatment of cardiac disease during cancer therapy has won him national recognition in the emerging field of cardio-oncology. He is one of the founding editors of the Cardio-oncology Journal and currently serves as Deputy Editor.

3 Ronny Drapkin, MD, PhD Ronny Drapkin, MD, PhD, is the Franklin Payne Associate Professor of Pathology in Obstetrics & Gynecology at Penn Medicine s Abramson Cancer Center and Director of the Ovarian Cancer Research Center. In addition, Dr. Drapkin is the Director of Gynecological Research at Penn Medicine s Basser Center for BRCA. His research, teaching, and clinical activities focus on understanding the pathogenesis and genetic alterations involved in women's cancers, with the intent to translate these important biological principles into clinically useful diagnostic and therapeutic tools. Dr. Drapkin s research has contributed to the vital discovery that many ovarian cancers actually begin in the fallopian tubes. Armed with this knowledge of where to detect ovarian cancer in its earliest stages, Dr. Drapkin and his team are poised to make advances in diagnosis and treatment advances that will save lives from a devastating disease that previously had few viable treatment options. Dr. Drapkin graduated from Rutgers University Graduate School of Biomedical Science and the Robert Wood Johnson Medical School. He completed his residency in Anatomic Pathology at Brigham & Women's Hospital in Boston, his postdoctoral fellowship at the Dana-Farber Cancer Institute, and then joined the Harvard Medical School faculty, where he was most recently an Associate Professor.

4 Kojo Elenitoba-Johnson, MD Kojo Elenitoba-Johnson, MD, is the inaugural Peter C. Nowell, MD Professor at the Perelman School of Medicine. He is also the Founding Director of Penn Medicine s Center for Personalized Diagnostics, as well as Chief of the Division of Molecular and Genomic Pathology. He was Professor of Pathology at the University of Michigan before joining Penn Medicine faculty in Dr. Elenitoba-Johnson is an international leader in the field of hematopathology and molecular pathology, as well as mass spectrometry-driven proteomics. His laboratory is credited with having identified a number of recurrent genetic abnormalities and signaling pathways associated with the development and progression of subtypes forms of lymphoma. Dr. Elenitoba-Johnson earned his MD from the College of Medicine at the University of Lagos, in Nigeria. He underwent residency training in Anatomic and Clinical Pathology at Brown University School of Medicine, and served as chief resident. He completed a fellowship at the National Cancer Institute, and completed Leadership Development for Physicians in Academic Health Centers at the Harvard School of Public Health. Dr. Elenitoba-Johnson has received several awards, including the Ramzi Cotran Young Investigator Award from the United States and Canadian Academy of Pathology and the American Society for Investigative Pathology Outstanding Investigator Award. He is a member of the America Society for Clinical Investigation.

5 Bonnie Ky, MD, MSCE Bonnie Ky, MD, MSCE is an Assistant Professor of Medicine and Epidemiology at the University of Pennsylvania School of Medicine Division of Cardiology, a Senior Scholar in the Center for Clinical Epidemiology and Biostatistics, and is the Director of the Penn Center for Quantitative Echocardiography. In this role, she is a leader in the burgeoning field of cardio-oncology and is recognized nationally and internationally. She leads a highly active NIH-funded translational research program aimed at identifying the underlying mechanisms and predictors of cancer therapy cardiotoxicity in many populations, including breast cancer, renal cell cancer, lung cancer, multiple myeloma, lymphoma, and leukemia. Specifically, her study objectives are to determine the role of mechanistic biomarkers, echocardiography-derived measures, and genetics in understanding and predicting incident cardiotoxicity and adverse cardiovascular outcomes with cancer treatment. She has specialized training in clinical epidemiology, the study of cardiovascular biomarkers, and the use of quantitative echocardiography as tools to understand cardiac remodeling and risk prediction. Dr. Ky received her a Bachelor of Science degree in Chemical Engineering from the Massachusetts Institute of Technology. She received her Doctor of Medicine degree from the University of Pennsylvania School of Medicine. She completed her residency and cardiology fellowship as well as a Masters of Science in Epidemiology at the University of Pennsylvania. Dr. Ky is an invited member of multiple cardio-oncology expert consensus groups, including those founded by the NIH, American College of Cardiology, the American Society of Clinical Oncology, FDA, Children s Oncology Group, American Society of Echocardiography, and American Heart Association. She chairs the Heart Failure Society of America Research Committee and the Eastern Cooperative Group Cardiotoxicity Working Group. She is Director of the inaugural American College of Cardiology Cardio-Oncology Course Advancing Cardiovascular Care of the Cancer Patient